Macrophages-Cancer Membrane Encapsulated Metal-Organic Frameworks with Copper-Depleting Moiety for Mitochondria-Targeted Therapeutic.

Abstract

Mitochondria-targeted therapeutics is an attractive approach against energy-dependent cancer. However, the effective mitochondria organelle therapeutics agents still highly desirable. Herein, we report a mitochondria-targeted therapeutics platform, termed CDM@MUiO-DP@MCHM, consisted of macrophages-cancer hybrid membrane (MCHM) encapsulated MUiO-66 metal-organic frameworks (MOFs), which was loaded with microRNA (miRNA) biomarker detection probe (DP) for cancer diagnosis and copper-depleting moiety (CDM) for mitochondrial copper depletion to suppress cancer growth. Using nude mice bearing MCF-7 as model, after injected intravenously via the caudal vein of mice, the encapsulation of MCHM can not only greatly enhance the cancer homing-targeting ability of the nanoparticles (NPs), but also endows the NPs the immune escape capacity to extend the circulation time. The miRNA-21 biomarker could be detected by the fluorescence signal for diagnosis, while the CDM induced energy deficiency of and compromised mitochondria membrane potential, leading to apoptosis of the cancer cell. The good performance of CDM@MUiO-DP@MCHM suggest the great potential mitochondria organelle therapeutics. This article is protected by copyright. All rights reserved.